The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Case of an Iron Overload Patient Who Discontinued Iron Chelation Therapy and Was Treated with Saenggangunbi-tang

철 킬레이트화 치료를 중단한 철과잉증 환자의 생간건비탕을 사용한 치험 1례

  • Juyoung Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Cho Hyun Hwang (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Eunkyung Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Eungyeong Jang (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Jang-Hoon Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Youngchul Kim (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
  • 이주영 (경희대학교 한의과대학 간계내과학교실) ;
  • 황조현 (경희대학교 한의과대학 간계내과학교실) ;
  • 이은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 장은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실)
  • Received : 2023.04.09
  • Accepted : 2023.05.22
  • Published : 2023.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study identified the effect of Korean medicine treatment on a patient with iron overload who discontinued iron chelation therapy. Methods: A 64-year-old woman with iron overload was treated with Saenggangunbi-tang from November 14, 2022, to March 15, 2023, to reduce fatigue and improve laboratory findings. We observed changes in the symptoms and improvement of laboratory findings during the four-month treatment. Results: The approximately four-month treatment with Saenggangunbi-tang showed considerable improvement in laboratory findings and fatigue. In addition, no adverse effects, such as liver injury, were observed during Korean medicine treatment. Conclusion: This study suggests the availability of Saenggangunbi-tang as a therapeutic option for managing patients with iron overload.

Keywords

References

  1. Kim H. Diagnosis and treatment of transfusion-related iron overload. Korean J Intern Med 2022;65(10):662-72. https://doi.org/10.5124/jkma.2022.65.10.662
  2. Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disroders. Hepatol Commun 2022;6(8):1842-54. https://doi.org/10.1002/hep4.2012
  3. Radford-Smith DE, Powell EE, Powell LW. Haemochromatosis: a clinical update for the practising physician. Intern Med J 2018;48(5):509-16. https://doi.org/10.1111/imj.13784
  4. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139(2):393-408. https://doi.org/10.1053/j.gastro.2010.06.013
  5. Fleming RE, Ponka P. Iron Overload in Human Disease. N Engl J Med 2012;366(4):348-59. https://doi.org/10.1056/NEJMra1004967
  6. McDowell LA, Kudaravalli P, Sticco KL. Iron Overload. StatPearls [Internet]. 2022. Available from: URL:https://www.ncbi.nlm.nih.gov/books/NBK526131/
  7. Siah CW, Trinder D, Olynyk JK. Iron overload. Clinica Chimica Acta 2005;358(1-2):24-36. https://doi.org/10.1016/j.cccn.2005.02.022
  8. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276(11):7806-10. https://doi.org/10.1074/jbc.M008922200
  9. Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 2022;139(20):3018-29. https://doi.org/10.1182/blood.2021011338
  10. McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325(2):53-62. https://doi.org/10.1097/00000441-200302000-00001
  11. Jang JH, Lee JH, Yoon SS, Jo DY, Kim HJ, Chung J, et al. Korean guideline for iron chelation therapy in transfusion-induced iron overload. J Korean Med Sci 2013;28(11):1563-72. https://doi.org/10.3346/jkms.2013.28.11.1563
  12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2017. Available from: URL: https://www.ncbi.nlm.nih.gov/books/NBK547852/
  13. Kim EJ, Hwang CH, Lee JY, Jang EG, Kimg YC, Lee JH. A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia. J Int Korean Med 2022;43(2):184-90. https://doi.org/10.22246/jikm.2022.43.2.184
  14. Choi HS, Jung TY. One Case of Drug-Induced Liver Injury Treated with Saenggangeonbi-tang. J Int Korean Med 2004;25(4):207-11.
  15. Choi JW, Kim GW, Shin MR, Roh SS. Effect of Haegan-jeon on Thioacetamide-Induced Liver Fibrosis. J Int Korean Med 2022;43(4):643-55. https://doi.org/10.22246/jikm.2022.43.4.643
  16. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003;361(9358):669-73 https://doi.org/10.1016/S0140-6736(03)12602-5
  17. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990;11(1):127-37. https://doi.org/10.1002/hep.1840110122
  18. Hong JH, Lee JW, Park JH, Lee IS. Antioxidative and cytoprotective effects of Artemisia capillaris fractions. Biofactors 2007;31(1):43-53. https://doi.org/10.1002/biof.5520310105
  19. Adams P, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25(1):162-6. https://doi.org/10.1002/hep.510250130
  20. Murphy A, Lee J, Slattery E. The real impact of fatigue in Haemochromatosis. In : Irish Society of Gastroenterology. ISG Summer Meeting; 2016, p. 20.